

REV-LON HEALTH CARE GROUP INTEROFFICE MEMORANDUM

DATE: March 15, 1984
TO: LIST
FROM: Michael B. Rodell, Ph.D.
SUBJECT: PLASMA DONOR TESTING
FOR ANTI-HBc

C.C. G. Lindell

file: Regulatory M

An industry-blood banking-government Study Group, for which I served as Chairman, recently met to consider the appropriateness of testing potential blood and/or plasma donors for the presence of Anti-HBc, as an additional means of identifying members of high risk groups associated with AIDS.

I was authorized by the Study Group to issue an Interim Summary Statement in advance of a full report being available. A copy of that statement is attached.

Please be aware that, although the majority of the Study Group members did not believe that Anti-HBc testing was appropriate for the purpose of high risk group identification, a minority opinion does exist. Conceivably, one or more organizations in the minority group could implement testing, thereby creating a "cascade" effect on the others. I have received promises from representatives of those organizations that they will advise me if any decision to implement testing is made.

I will be working closely with John Sedor and Ty Foster to see that we are closely tied in with the unanimous recommendations made by the Study Group regarding pilot programs for "directed donation" and P-2-microglobulin testing.

MBR:ag

LIST: S. Beling, M.D.
A. Bessler
L. Burg
T. Foster
R. Havens
S. Johnson
D. Marcus, Ph.D.
J. O'Brien
P. Roberts, M.D.
S. Samuels
L. Schnell, Ph.D.
J. Sedor
C. G. Smith, Ph.D.
C. Stroupe
C. Swartz, Ph.D.

GRO-C, Rodell



MFK 001297

72610

PLTF000333

CGRA0000646_0001